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An in vitro binding system is described to display large full-length proteins on bacteriophage T4 capsid surface at high density. The phage T4
icosahedral capsid features 155 copies of a nonessential highly antigenic outer capsid protein, Hoc, at the center of each major capsid protein
hexon. Gene fusions were engineered to express the 83-kDa protective antigen (PA) from Bacillus anthracis fused to the N-terminus of Hoc and
the 130-kDa PA-Hoc protein was expressed in Escherichia coli and purified. The purified PA-Hoc was assembled in vitro on hoc phage
particles. Binding was specific, stable, and of high affinity. This defined in vitro system allowed manipulation of the copy number of displayed PA
and imposed no significant limitation on the size of the displayed antigen. In contrast to in vivo display systems, the in vitro approach allows all
the capsid binding sites to be occupied by the 130-kDa PA-Hoc fusion protein. The PA-T4 particles were immunogenic in mice in the absence of
an adjuvant, eliciting strong PA-specific antibodies and anthrax lethal toxin neutralizing antibodies. The in vitro display on phage T4 offers a novel
platform for potential construction of customized vaccines against anthrax and other infectious diseases.
D 2005 Elsevier Inc. All rights reserved.Keywords: Bacteriophage T4; Virus assembly; Hoc; Phage display; Protective antigen; VaccineIntroduction
In phage display, a foreign peptide, domain, or protein, is
fused to a virus structural protein and exposed on the outer
surface of the virus particle (Smith and Petrenko, 1997). The
coat proteins of filamentous phages (M13, fd, and f1), the minor
coat protein pIII (4–5 copies) and the major coat protein pVIII
(2700 copies), have been extensively used primarily to display
libraries of six to eight amino acid (aa) peptides (Smith, 1985;
Markland et al., 1991). Other display systems using icosahedral
phages l [gene product (gp) D, the capsid decoration protein,
420 copies; gpV, the major tail protein, 192 copies] (Sternberg
and Hoess, 1995; Maruyama et al., 1994) and T7 (gp10, the
major capsid protein, 415 copies) (Rosenberg et al., 1996;0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.10.037
* Corresponding author. Fax: +1 202 319 6161.
E-mail address: rao@cua.edu (V.B. Rao).Castillo et al., 2001) can display larger peptides and domains
derived from targeted genes or c-DNA libraries.
While these systems have been enormously successful for
displaying combinatorial libraries of short peptides, they also
possess certain inherent limitations (see Smith and Petrenko,
1997; Manoutcharian et al., 2001; Castagnoli et al., 2001;
Hoess, 2002). With the filamentous phages, display of certain
peptides is restricted, or not possible, since the fused peptide
may not be able to successfully pass through the E. coli
envelope where the coat protein assembly occurs. Since the
phage structural proteins used in the above display systems are
normally essential or conditionally lethal, display is inefficient
because the fusion proteins, particularly those fused to large
peptides and domains, interfere with the virion assembly. It is
often necessary to express wild-type protein along with the
recombinant fusion protein in order to generate viable phage
(Maruyama et al., 1994; Mikawa et al., 1996).6) 190 – 198
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exploited for phage display. The prolate icosahedral capsid
shell (T = 20; width, 86 nm; length, 119.5 nm; Fokine et
al., 2004) consists of three essential proteins: 930 copies
(155 hexamers) of the major capsid protein, gp23* (49 kDa;
blue subunits; ‘‘*’’ represents the cleaved mature form), 55
copies (11 pentamers) of the minor capsid protein gp24* (46
kDa; purple subunits) at eleven of the twelve vertices, and
12 copies (1 dodecamer) of the portal protein gp20 (61 kDa;
capsid-proximal ring as part of the green structure at the
base) at the twelfth vertex through which DNA enters and
exits (Fokine et al., 2004; Black et al., 1994).
Two outer capsid proteins, Hoc (highly antigenic outer
capsid protein; 39 kDa, yellow subunits) and Soc (small
outer capsid protein; 10 kDa, white subunits), decorate the
phage T4 outer capsid surface (Fig. 1A; Ishii and Yanagida,
1975, 1977). Hoc is present up to 155 copies per capsid
with each monomer occupying the center of the gp23*
hexon, and Soc is present up to 810 copies per capsid with
each monomer bridging two gp23* monomers of adjacent
hexons (Fokine et al., 2004; Iwasaki et al., 2000). The Soc
subunits form an outer ‘‘cage’’ providing additional stability
to the capsid. The functional significance of Hoc is
unknown. Sequence alignments suggest that Hoc encodes
IgG-like domains (Bateman et al., 1977), which may be
involved in interactions with the bacterial surface.
Most important, both Hoc and Soc, unlike the structural
proteins used in other phage display systems, are nonessential
and assembled on the capsid lattice following the completion of
assembly (Ishii and Yanagida, 1975; Black et al., 1994). Null
(amber or deletion) mutations in either or both the genes do not
affect phage production, phage viability, or phage infectivity.
Foreign domains/proteins can be fused to the N- and C-termini
of Hoc or Soc and displayed on the capsid (Ren et al., 1996;
Jiang et al., 1997; Ren and Black, 1998).
All the phage display systems previously reported,
including the T4 system, are in vivo-based, i.e., expression
and assembly of the foreign peptide/protein occurs duringFig. 1. Schematics of the recombinants. (A) Anthrax PA displayed on bacteriophage T
(Petosa et al., 1997) to the Hoc monomer (yellow spikes) of phage T4 cryo-EM recon
purple, Soc in white, PA in red, portal, neck, and part of the tail in green. (B) Schem
1989; Rao and Mitchell, 2001) was used to fuse PA and Hoc genes via the linkerphage infection. This is problematic for the display of large
domains and full-length proteins because variations in
intracellular expression, aggregation of the expressed protein,
nonspecific proteolysis, and interference with phage assem-
bly often result in inefficient display, lack of structural
homogeneity, and large differences in the copy number of
the displayed protein. In phage l display, of the 192 copies
of gpV per virion, only ¨1 copy of gpV-h-galactosidase
fusion (116 kDa) was incorporated into phage (Maruyama et
al., 1994), and only ¨34 copies of the 420 copies of gpD
were present as an equivalent fusion protein (Mikawa et al.,
1996; Hoess, 2002). In the T7Select display system, of the
415 copies of gp10, only 0.1–1 copy of gp10-h-galactosi-
dase fusion was assembled (Rosenberg et al., 1996). In
phage T4 display, about 25–100 copies of Soc-VP1 (VP1; a
33-kDa fragment of poliovirus capsid protein) were dis-
played of the possible 810 copies (Ren et al., 1996), and
20–40 copies of Hoc-CD4 (CD4; a 20-kDa fragment of the
HIV receptor) were displayed of the possible 155 copies
(Ren and Black, 1998). In our own published work, the
copy number of displayed PorA-Soc (PorA; a 4-kDa porin
peptide from Neisseria meningitidis) varied between 10 and
>100% of the expected copy number in different prepara-
tions (Jiang et al., 1997). In addition, nonspecific proteolysis
of both the displayed Hoc and Soc fusion proteins and
display of aggregated protein were evident (Ren et al., 1996;
Jiang et al., 1997). Although Brenner and colleagues
developed an in vivo suppression strategy, which can control
the fusion protein expression to some extent (Maruyama et
al., 1994; Mikawa et al., 1996), very little, if any, control
can be exerted on other in vivo display parameters in order
to generate particles of desired composition.
The above limitations are quite serious for applications
such as vaccine development, structural biology, and
quantitative biochemistry, wherein particles displaying a
defined copy number of biologically active molecules are
needed. An attractive strategy would be to perform the
binding reaction in vitro using purified and functionally4. The hypothetical structure is generated by merging the X-ray structure of PA
struction reported by Fokine et al. (2004). The gp23* is shown in blue, gp24* in
atic of PA-Hoc fusion constructs. The PCR-based SOE strategy (Horton et al.,
as shown.
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would allow display of any protein(s) of interest without
significant restrictions on size, while manipulation of the
binding parameters can control its copy number.
In this study, we hypothesized that large full-length proteins
tagged to Hoc, such as the 83-kDa protective antigen (PA) from
B. anthracis (red projections on Hoc subunits; Fig. 1A), can be
displayed in vitro through specific protein–protein interactions
between Hoc and the symmetrically arranged binding sites
within the gp23* hexamers. Such a system will allow
manipulation of phage T4 capsid surface under controlled
conditions. PA, the target protein used in this study, is the
principal component of the tripartite anthrax toxin and its
interactions with the cellular receptors, TEM8 and CMG2, and
the two toxin partners, lethal factor (LF, 90 kDa; zinc
metalloprotease), and edema factor (EF, 89 kDa; adenyl
cyclase), are critical for the mechanism of toxin action (Leppla,Fig. 2. Expression and purification of PA-Hoc fusion proteins. (A) Full-length PA-Ho
and 2: E. coli samples either before or after (2.5 hr) IPTG induction; lanes 3 and 4: sup
for 10 min); lane 5: purified protein after HisTrap chromatography; lanes 5A and 5B
polyclonal PA antibodies; lane PA: mature PA standard; lane M: MW standards. The
were electrophoresed on a 10% SDS-PAG and stained with Coomassie blue R-250. (D
(16 mm  60 cm) equilibrated with 50 mM Sodium phosphate pH 7.0, 200 mM N
calibration of the column (Top axis) are shown. (E) Native 4–12% gradient PAGE of
followed by staining with Coomassie blue.1999; Friedlander, 2000). Antibodies that interfere with these
interactions neutralize toxicity (Leppla et al., 2002; Mourez,
2004). Thus, the PA, with its large size and being the principal
target for anthrax vaccine development, is an excellent model
antigen to display on T4. The main goal of this study, however,
is to rigorously test the basic hypotheses for in vitro binding,
which should unveil new avenues for protein engineering of
the T4 capsid surface.
We report here the development of an in vitro display system,
which demonstrates that the Hoc–capsid interactions allow
efficient binding of the 130-kDa PA-Hoc fusion protein on
bacteriophage T4. The system is exquisitely specific for binding
of the Hoc-tagged PA and allows control over the copy number
of the displayed antigen. The in vitro assembled PA-T4 particles
are immunogenic in mice in the absence of any external
adjuvant, eliciting high titer antibodies and anthrax lethal toxin
neutralization titers. To our knowledge, this represents the first inc; (B) mature PA-Hoc; (C) Western blot with polyclonal PA antibodies. Lanes 1
ernatant and pellet of homogenate following low speed centrifugation (6000 rpm
: Western blotting of purified full-length and mature PA-Hoc respectively with
thick and thin arrows correspond to PA-Hoc and PA respectively. The samples
) The HisTrap-purified PA-Hoc was loaded on a HiLoad Superdex 200 column
aCl, and 1 mM MgSO4. The protein elution profile (Peaks I and II) and MW
the HisTrap purified starting sample (lane 1), Peak-I (lane 2) and Peak-II (lane 3),
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The basic approaches described here can be potentially
expanded to develop novel multicomponent vaccine platforms
against anthrax and other infectious diseases.
Results
Cloning, expression, and purification of PA-Hoc
Three gene fusions were engineered: full-length PA-Hoc,
mature PA-Hoc in which the N-terminal signal sequence (aa 1–
29) was deleted, and mature linker-less PA-Hoc (Fig. 1B), all
with a N-terminal hexa-histidine tag (see Materials and
methods). The fusion proteins were expressed up to about 8–
10% of the total E. coli protein (Fig. 2, compare lanes 1 and 2 in
panels A and B). About 80% of the mature PA-Hoc proteins
remained in the soluble fraction (panel B, lanes 3 and 4) whereas
>90% of the full-length PA-Hoc remained in the insoluble
fraction (panel A, lanes 3 and 4). All the proteins were purified
by HisTrap affinity chromatography (lane 5, panels A and B). In
the case of full-length PA-Hoc, the protein was denatured from
the insoluble inclusion bodies and renatured during HisTrap
chromatography. Western blotting with anti-PA antibodies
specifically recognized the PA-Hoc band in the crude lysate as
well as the purified sample (panel C and data not shown).
Analysis of the HisTrap-purified PA-Hoc by native PAG
showed two bands, a diffused band near the well and a sharp
band near the bottom of the gel (panel E, lane 1; only the data for
mature PA-Hoc, referred to as PA-Hoc, are shown for the rest of
the experiments; the other two constructs were also used and
gave very similar results). These were separated into nonover-
lapping peaks by gel filtration on Superdex-200 (panel D; lanes 2
and 3 in panel E). Peak-I eluted close to the exclusion limit (600
kDa) of the gel matrix suggesting that it represents a multimeric
fraction. Peak-II eluted at the position expected for a dimer of
PA-Hoc (apparent MW: 252 kDa), although we suspected this
species to be a monomer based on the fact that both Hoc and PAFig. 3. Nicking of PA-Hoc and in vitro binding of nicked PA63-Hoc to LF and EF. PA
in 20 mM Tris–HCl, pH 7.5, and 100 mM NaCl. The reaction was stopped by adding
out at 25 -C for 30 min in 25 mM Tris–HCl, pH 9.0 containing 2 mg/ml CHAPS. T
and stained with Coomassie blue. Lanes: 1, PA; 2, PA-Hoc; 3, nicked PA63; 4, nicke
nicked PA63 + EF; 10, nicked PA63-Hoc + EF.exist as a monomer in solution (Black et al., 1994; Leppla,
1999). Sedimentation velocity data as obtained by analytical
ultracentrifugation showed that peak-II indeed sedimented as a
monomer (for methodologies used, see Shuck, 2000; Dam and
Schuck, 2004). We therefore infer that the PA-Hoc molecule
possesses an unusually high Stokes radius, behaving as a much
larger protein, a dimer, under size exclusion conditions imposed
by the porous gel matrix. It is interesting that fusion of the flat,
linear, four-domain PA structure (Petosa et al., 1997) to a
relatively unstructured hexa-His tag on the N-terminus and a
rod-shaped Hoc to the C-terminus resulted in a large shape
asymmetry.
The PA and Hoc domains of the PA-Hoc fusion protein are
folded into a native conformation
Several lines of evidence demonstrated that fusion of the 83-
kDa PA toHoc did not interfere with the folding of either protein.
Quantitative ELISA assays using the 14B7 neutralizing mono-
clonal antibody against a conformational epitope in PA domain-
4 (Leppla et al., 2002) showed that the purified PA-Hoc was
captured as efficiently as the native PA. In numerous experi-
ments using independent PA-Hoc preparations, the PA-Hoc was
nicked to PA63-Hoc at the same trypsin ratio as the native PA.
The nicked PA63-Hoc interacted with native LF and EF and
formed appropriate size complexes as determined by native
polyacrylamide gel electrophoresis (PAGE) (Fig. 3; compare
lanes 7 and 10 corresponding to PA63-Hoc-LF and PA63-Hoc-
EF complexes with lanes 6 and 9 corresponding to native PA63-
LF and PA63-EF, respectively). It has been well documented
that, following proteolytic cleavage, PA63 heptamerizes and
interacts with LF and/or EF to form higher order complexes
(Leppla, 1999; Singh et al., 1999). The gel migration patterns of
our PA63-LF/EF complexes (Fig. 3) were similar to those
reported in literature, suggesting that the nicked PA63-Hoc, like
the native PA63, formed heptamers and interacted with LF or EF.
With regard to the Hoc domain, the integrity of the capsid-Hoc and PAwere digested with trypsin (1 ng/Ag of protein) at 25 -C for 30 min
TLCK trypsin inhibitor (200 Ag/1 ng trypsin). Binding to LF or EF was carried
he samples were electrophoresed on a native 4–12% gradient PAG (Invitrogen)
d PA63-Hoc; 5, LF; 6, nicked PA63 + LF; 7, nicked PA63-Hoc + LF; 8, EF; 9,
Fig. 4. In vitro binding of PA-Hoc on hocsoc T4 phage particles. Purified PA-Hoc, PA, and/or BSA were incubated with hocsoc phage in 50 mM sodium
phosphate pH 7.0, 75 mMNaCl, and 1 mMMgSO4. Phage were sedimented by high-speed centrifugation (13,000 rpm for 1 h), and the pellet was washed twice with 1
ml of buffer, resuspended in 10 Al of buffer, and transferred to a new Eppendorf tube. Both the supernatant and pellet samples were electrophoresed on a 10% SDS-PAG
and stained with Coomassie blue. Lanes 2, 4, 6, 8, 10, and 12: unbound protein in the supernatant; lanes 3, 5, 7, 9, 11, and 13: phage pellet following incubation and
washing; lane 14, Western blotting and immunostaining of lane 3 with polyclonal PA-specific antibodies; lane M, MW standards.
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efficiently bound to the hocsoc phage particles (see below).
Preliminary cryo-EM reconstructions showed the presence of
intact Hoc structure in the displayed particles (A. Fokine, T.
Batista, P. Chipman and M. Rossmann, personal communica-
tion). Finally, both the PA and Hoc domains were reconstituted
to the native form following urea denaturation and renaturation.
Taken together, these data suggest that the Hoc fusion strategyFig. 5. Quantitative analysis of the in vitro binding of PA-Hoc on phage T4. (A) A
purified PA-Hoc monomer (Peak-II; Fig. 2D) to the number of Hoc binding sites (sho
Lanes: 1, control phage; 2, PA-Hoc standard; 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, u
PA-Hoc (pellet). The positions of PA-Hoc, gp18 (71 kDa, 144 copies) and gp23*
volumes of the bound and unbound PA-Hoc and gp23* were quantitated by laser den
gp23* (930 copies per particle) in the respective lane, and the copy number of PA-H
binding curve (C). The data were fitted by nonlinear regression using the GraphPad P
molecules per phage particle; r2: degree of confidence.allows correct folding of fused domains/proteins, an important
validation of this approach for developing the in vitro binding
system.
Display of PA-Hoc by in vitro binding
Sucrose gradient-purified hocsoc T4 particles were
incubated with purified PA-Hoc and sedimented by high-speedbout 1010 hocsoc particles were incubated with increasing ratios of FPLC-
wn at the top). Binding conditions are the same as described in legend to Fig. 4.
nbound PA-Hoc (supernatant); 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, phage-bound
(49 kDa, 930 copies) bands are marked with an arrow. (B and C) The density
sitometry. The density of 130-kDa PA-Hoc was normalized to that of the 49-kDa
oc per particle was determined and depicted as a histograph (B) or a saturation
RISM-4 software. Kd: association constant; Bmax: maximum number of PA-Hoc
Fig. 6. Immunogenicity of T4-displayed PA-Hoc. Female CBA/J mice (10
mice/group) (Jackson Labs, Maine) were immunized with the antigens as
described in Materials and methods. Serum PA-specific IgG titers were
determined by ELISA at week 8 following the primary immunization (Matyas
et al., 2004). The end point titer is defined as the highest serum dilution giving
2-times the mean OD405 values obtained with the negative control. Lethal
toxin neutralizing antibody titers (ED50) were determined using the mouse
macrophage-derived J774A.1 cells (ATCC, Manassas, Virginia) and colori-
metric cytotoxicity assay (Matyas et al., 2004). The bars represent geometric
mean antibody titers T geometric mean error. Statistical analysis was performed
using the paired two-tail Student’s t test.
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cifically bound protein, the pellet was analyzed by SDS-PAGE.
The data showed that a new band corresponding to the 130-kDa
PA-Hoc appeared with the phage particles (Fig. 4; compare lane
3with control lane 1), suggesting that the recombinant PA is now
part of the T4 phage. This band was specifically stained with PA-
specific antibodies (lane 14).
Specificity of in vitro assembly
The interaction between PA-Hoc and hocsoc phage is
highly specific. Neither the control PA nor BSA showed
significant association with the phage particles (Fig. 4; lanes 5
and 7). When all three components, PA-Hoc, PA, and BSA, were
present in the reaction mixture, only PA-Hoc was selectively
assembled on the hocsoc phage (lanes 9, 11, and 13). Even at
saturating concentrations of each protein (30:1 ratio each of
BSA, PA, and PA-Hoc molecules to number of Hoc binding
sites), only PA-Hoc was selectively taken up by the hoc phage,
demonstrating that fusion to Hoc is obligatory for assembly of
PA on the T4 capsid. The interaction between the displayed PA-
Hoc and T4 capsid is very stable. No significant dissociation of
PA-Hoc occurred following treatment of displayed PA-T4
particles with pH 2 buffer or 4 M urea (data not shown).
Copy number of the displayed PA
Recent cryo-EM reconstructions determined that the precise
copy number of Hoc per wild-type phage particle is 155 (Fokine
et al., 2004). One Hoc monomer is visualized at the center of
each gp23* hexon, but not the penton vertices formed by the
homologous gp24* (Fig. 1A). The ratio of PA-Hoc molecules to
capsid binding sites was varied in the reaction mixture, and the
copy number of bound PA-Hoc per particle was determined by
laser densitometric quantification of the Coomassie blue-stained
band and normalizing it with the control gp23* for which the
copy number is known to be 930 per particle. The data were also
cross-checked with the known copy number of the tail sheath
protein, gp18 (144 copies per particle).
Quantitative binding experiments using pure PA-Hoc mono-
mer showed increased binding with increasing ratio of PA-Hoc
molecules to binding sites and reached the maximum at a ratio of
about 30:1 (Fig. 5, panel A, lanes 3–12). Higher ratios up to
100:1 showed no additional binding (lanes 13–22). The
maximum copy number per phage particle was 173 (panels B
and C), which confirms the predicted mode of Hoc binding, i.e.,
one PA-Hoc monomer per each gp23* hexon. Binding reached
near saturation at a relatively low ratio of 10:1 (250 nM PA-
Hoc). The apparent Kd for association is 69 nM (panel C),
suggesting a high affinity interaction between PA-Hoc and
gp23* hexon.
Immunogenicity of PA-T4 particles
The immunogenicity of T4-displayed PAwas tested in mice.
The PA-specific IgG antibody titers and the lethal toxin
neutralizing antibody titers were compared with mice immu-nized with PA-Hoc, wild-type T4, and as a positive control, PA
adsorbed to alum. Although twice the molar equivalent of PA-
alum than T4-displayed PA was used for immunization, T4-
displayed PA gave the highest PA-specific antibody titers (Fig.
6). The geometric mean titer of 1.4 million for T4-PAwas 2-fold
higher (P = 0.01) than that obtained with PA-alum (0.7 million;
Fig. 6). Although lethal toxin neutralization titers (ED50) of PA-
T4 were 2.5-fold less than those of PA-alum, they were higher
than those induced by PA-Hoc. Importantly for the potential use
of T4 display to serve as an immunogen, T4-displayed PA gave a
6.5-fold higher antibody titer (P = 0.0003) and a 4.7-fold higher
ED50 (P = 0.007), relative to those immunized with PA-Hoc.
Thus, the immunogenicity of PA-Hoc was enhanced when
displayed on the surface of a T4 particle.
Discussion
Bacteriophage T4 is a highly stable particle with precise
dimensions (T = 20; width, 86 nm; length, 119.5 nm; Fokine et
al., 2004), which is decorated with a combined total of 965
copies of two nonessential outer capsid proteins, Hoc and Soc
(Fig. 1A). In principle, all 965 copies can be replaced with
foreign proteins fused to Hoc and Soc. In this study, we have
demonstrated that fusion of 83-kDa PA to the N-terminus of Hoc
does not interfere with the folding or functional integrity of
either protein. Moreover, under defined conditions, the PA-Hoc
fusion protein can be efficiently immobilized on the T4 capsid
surface. Thus, the phage T4 system provides an excellent
binding site-enriched platform that can be manipulated by in
vitro binding.
The basic design of foreign gene fusion to Hoc for in vitro
display is fundamentally similar to that used for in vivo display.
The addition of hexa-histidine tag is important for in vitro
display in order to rapidly purify the Hoc-PA fusion protein.
Based on the available literature and this study, his-tag addition
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the displayed protein. Further purification by FPLC gel filtration
is necessary since it separates out the aggregated protein that is
commonly present in all over-expressed preparations and for
quantitative functional characterizations. Combined with a
relatively simple in vitro binding reaction, these strategies
allowed rapid production of the displayed PA-T4 particles. A
number of proteins such as the anthrax LF (90 kDa) and EF (89
kDa) and HIV p24 (24 kDa) have been successfully displayed
using the same strategies (unpublished data), attesting to the
general applicability of this system to any protein of interest. The
basic principles should also be applicable to develop an in vitro
Soc binding system, whichmay allow a higher density display of
the target protein or domain, up to 810 copies per particle (in
progress). Thus, the in vitro approach overcomes some of the
limitations of the in vivo display systems (as described in the
Introduction), allowing the loading of purified and functionally
well-defined foreign proteins on the phage capsid surface.
Quantitative binding data showed that, by varying the ratio
of PA molecules to phage particles, a desired copy number of
the antigen can be attained, or the binding sites can be fully
occupied with the PA (Fig. 5). Considering that one Hoc
monomer binds to the center of gp23* hexon, cooperativity of
Hoc binding to the capsid sites is unlikely. Therefore, under
subsaturating concentrations (<500 nM PA-Hoc), PA-Hoc is
expected to be evenly distributed on the T4 particles. Full
occupancy occurred at a relatively low PA-Hoc:particle ratio
(20:1, 500 nM PA-Hoc) with an apparent Kd of 69 nM,
indicating a high affinity interaction even when Hoc is attached
to a large protein mass. These parameters remained unchanged
in the presence of a large excess of nonspecific proteins such as
BSA and PA (Fig. 2). The fact that treatment with pH 2 buffer
or 4 M urea did not dissociate the displayed PA indicates a
strong and stable interaction between Hoc and the capsid
binding site. These are significant points, which suggest that
quantitative biochemical parameters using purified and well-
characterized components, but not the variations in expression
efficiency, aggregation, proteolysis, etc. that are uncontrollable
in the in vivo display systems, dictate the in vitro system.
Evidence suggests that the T4 in vitro display system does
not impose significant limitations on the size of the displayed
antigen. The 140-A˚ distance between Hoc monomers of the
adjacent hexons (Fokine et al., 2004; Iwasaki et al., 2000) is
sufficient to stably display the 130-kDa PA-Hoc to the full
capacity of available binding sites. The binding behavior of
linker-less PA-Hoc, which mirrored that of linker-plus clones,
suggests that the N-terminus of Hoc is in a structurally stable
environment and not significantly perturbed by the large mass
of attached PA. Since most proteins are less than 91 kDa (PA
plus his-tag and linker; Fig. 1B), the size per se should not be a
factor for the in vitro display system. Furthermore, we have
successfully immobilized multimeric PA-Hoc (the void volume
fraction in Fig. 2D; >600 kDa) as well as the complete anthrax
toxin complex consisting of heptameric PA63 attached to LF-
Hoc and EF (675 kDa) (unpublished data). Thus, the Hoc–
capsid interactions are strong enough to stably anchor large
macromolecular complexes on the capsid surface.The in vitro displayed T4-PA particles are immunogenic in
mice without any externally added adjuvant. Consistent with
the earlier data (Ren et al., 1996; Jiang et al., 1997), display on
T4 conferred substantial boost to the immunogenicity of PA.
Although the mechanism is unknown, the particulate nature of
the antigen, high antigen copy number per particle, and
congregation of antigen presenting cells at the site of
immunization may have contributed to elicitation of strong
immune responses. While the total PA-specific antibody titers
for T4-displayed PAwere 2-fold higher than that obtained with
PA-alum, the ED50 titers were 2.5-fold lower. The latter, at
least in part, may be due to the inaccessibility of the
neutralization epitope in the C-terminal PA domain-4 as it is
linked to the N-terminus of Hoc (Leppla et al., 2002). This
hypothesis is being tested by analyzing the immunogenicity of
PA linked to the C-terminus of Hoc and other PA recombinants
that expose this epitope as well as the host receptor-binding site
in domain-4 on T4 capsid surface.
We envision many applications for the in vitro assembled
T4 particles. Since a cryo-EM reconstruction of the asymmetric
T4 particle was recently achieved (Fokine et al., 2004),
resolution of the structure of the displayed protein is possible.
The displayed protein can be used as a ‘‘bait’’ to ‘‘fish out’’ the
interacting target partner(s) from a library of molecules in an in
vitro two-hybrid format. A multicomponent T4 particle
displaying more than one protein from the same or different
infectious agents can be generated by mixing the respective
components in the in vitro assembly reaction. Additional
targeting and/or enhancing molecule(s) (e.g., CD40 ligand,
cytokine, etc.) can be displayed to target particles to certain
antigen presenting cells and further boost the immune
responses. A second display layer can be built over the first
through protein–protein interactions with the displayed anti-
gen. Cloning the gene(s) of the displayed antigen(s) into the T4
genome under the control of a strong promoter would generate
‘‘protein-outside/gene-inside’’ particles, which can be used as
prime boost immunogens. A combination of these strategies
will provide tremendous flexibility to manipulate the T4
platform and potentially allow the construction of customized
vaccines against a particular infectious agent(s). Some of these
strategies are currently under experimentation to expand the
basic in vitro assembly system described here.
Materials and methods
Bacteriophage, bacteria, and plasmids
The hocsoc phage (hoc-Q21am; soc-deletion) was con-
structed by a standard cross of hoc and soc phages. E. coli
P301 (sup-) was used to prepare hocsoc and other phage
stocks. E. coli XL-10 Gold cells (Stratagene) were used to
initially transform and stably maintain the recombinant con-
structs. The clones were then transferred into the expression
strains E. coli codon-plus BL21 (DE3) RIL/RIP (Stratagene) to
allow IPTG-induced over-expression of PA-Hoc fusion proteins
(Studier et al., 1990). The T7 expression plasmid pET-15b
(Ampr) (EMD Biosciences, Inc) was used as the cloning vector.
S.B. Shivachandra et al. / Virology 345 (2006) 190–198 197Plasmid pPA26 was used as a template for amplification of the
PA gene (pagA) (Welkos et al., 1988) for construction of fusion
proteins.
Construction of PA-Hoc gene fusions
PCR-based splicing by overlap extension (SOE) was used to
construct full-length (contains the N-terminal 29-aa signal
sequence), mature (no signal sequence), and mature linker-less
(no 7-aa linker sequence between PA and Hoc), PA-Hoc gene
fusions (Fig. 1B). The four primers and two successive PCRs
required to engineer the gene fusions were designed using the
basic principles described earlier (Horton et al., 1989; Rao and
Mitchell, 2001).
Gene fusions were designed in such a way that the full-
length and mature PA-Hoc clones incorporated a 7-aa linker
that encodes a flexible, structureless sequence, pro-gly-gly,
which was incorporated to minimize interference, if any,
between the PA and Hoc structural domains, and a cleavage
site for protease Xa, Ile-Glu-Gly-Arg, which allows excision of
PA from the fusion protein (Fig. 1B). The termination codon of
PA gene was deleted, and the 3V-end was fused in-frame to the
5V-end of Hoc via the linker sequence.
Amplified recombinant DNAs were purified by agarose gel
electrophoresis and inserted in-frame into the BamH1 site of
the pET-15b vector (EMD Biosciences, Inc). The 5V-end
primers were designed so that the insertion resulted in in-
frame fusion of PA-Hoc with the upstream vector sequence
corresponding to the 25-aa peptide containing the hexa-
histidine sequence (Fig. 1B).
Purification of anthrax toxin and PA-Hoc fusion proteins
Recombinant PA and LF were produced in B. anthracis
strain BH445 and purified by the procedures described earlier
(Park and Leppla, 2000; Ramirez et al., 2002). Recombinant
EF null mutant K346R was constructed and purified in the
laboratory (unpublished data). All these are mature proteins
consisting of no N-terminal signal sequence.
As indicated above, all the PA-Hoc constructs consisted of a
hexa-histidine tag at the N-terminus (Fig. 1B). The proteins were
over-expressed by IPTG induction, and the cells were lysed by
French-press treatment (Aminco, USA). The mature PA-Hoc
and mature linker-less PA-Hoc were present in the soluble
fraction, whereas the full-length PA-Hoc partitioned into the
insoluble fraction. The latter was solubilized by treatment with
the denaturing buffer (8 MUrea, 0.1M sodium phosphate, pH 8,
300 mM NaCl and 20 mM imidazole). The PA-Hoc proteins
were purified by HisTrap affinity chromatography (AKTA-
prime, GE Healthcare) followed by Superdex-200 gel perme-
ation chromatography (AKTA-FPLC, GE Healthcare).
In vitro display of PA-Hoc on T4 particles
The hocsoc phage was grown on E. coli P301 and purified
by 25–50% linear sucrose gradient centrifugation (Doermann et
al., 1973). Phage was dialyzed against the binding buffer (50mM sodium phosphate, pH 7.0, 75 mM NaCl, and 1 mM
MgSO4) and stored at 4 -C. About 1–2  1010 phage particles
(equivalent to plaque forming units) were centrifuged at 13,000
rpm for 1 h. The pellets were resuspended in 10 Al of binding
buffer, and the purified PA-Hoc was added at the desired
concentration in a total reaction mixture of 100 Al and incubated
at 37 -C for 45 min. Phage were sedimented by centrifugation as
above, the pellet was washed twice with 1 ml of binding buffer,
resuspended in 10 Al of the same buffer, and transferred to a new
Eppendorf tube for analysis by SDS-PAGE (low-bind Eppen-
dorf tubes were used to minimize nonspecific binding of protein
to the tube. It is however necessary to transfer the final
resuspension to a new tube to eliminate the release of any
background PA-Hoc stuck to the tube during boiling with the
SDS sample buffer).
Quantification of the copy number of the displayed PA-Hoc
A constant number of phage T4 particles (1010) were
incubated with increasing amounts of PA-Hoc. The ratio of PA-
Hoc molecules to Hoc binding sites was varied from 1:1 to
100:1. The standard in vitro binding conditions as described
above were followed, and the Coomassie blue-stained gels
were scanned using a PDSI laser density scanner (GE Health
Care). Using appropriate control lanes, the density volumes of
gp23* and PA-Hoc bands were quantified for each lane. The
copy number of PA-Hoc was calculated using the known copy
number of gp23*, which is 930 copies per particle. The data
were fitted for one-site binding by nonlinear regression using
the GraphPad PRISM-4 software (San Diego, CA). The data
were also cross-checked with the known copy number of gp18
(144 copies per particle) for consistency.
Immunization
Six-week-old female CBA/J mice (10 mice/group) (Jackson
Labs, Maine) were injected by the intramuscular route with 50
Al of the following antigens: soluble PA-Hoc (1.8 Ag); T4
displayed PA-Hoc (277 nM; 1010 hocsoc particles display-
ing 1.8 Ag PA-Hoc); T4 (1010 wild-type T4 particles); PA-alum
(578 nM; 2.4 Ag PA adsorbed to 100 Ag aluminum)
(Rehydrogel-HPA, Reheis Inc., Berkley Springs, New Jersey).
Animals were boosted with the same amounts of the antigens 4
weeks after the primary immunization. Serum PA-specific IgG
titers and lethal toxin neutralizing antibody titers (ED50) were
determined at week 8 post-immunization (Matyas et al., 2004).
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